Kornimate/medical-research-clean huggingface dataset:
study of the life stories of patients making a request for euthanasia, in the context of advanced cancer.

Conditions: Advanced Cancer

Summary: this study wishes to focus on the life course of patients, beyond the moments of suffering experienced at the time of the request for euthanasia. it is based on the perspective that the patient's account of his or her life course can be a source of information for better understanding and accompanying patients requesting euthanasia.


Eligibility criteria:
inclusion criteria: * major patients * with cancer in the palliative phase, i.e. with an incurable disease according to current knowledge. * expressing a request for euthanasia in terms evoking a request for death with the intervention of an outside person. * non-opposition to the study after full written information. exclusion criteria: * severe decompensated psychiatric pathology * vulnerable persons defined here as pregnant women, parturients and persons under legal protection or unable to express their consent * inability to conduct an interview

Keywords: euthanasia cancer
trans-catheter chemo-embolization combined with rad-p53 gene injection in treatment of advanced hepatocellular carcinoma

Conditions: Advanced Adult Hepatocellular Carcinoma

Summary: treatment options for advanced hepatocellular carcinoma (hcc) are limited due to patients' poor condition, advanced tumor, concomitant intra- and extra-liver diseases, and resistance to both chemo- and radio-therapy. trans-catheter embolization (tae) or trans-catheter chemo-embolization (tace) is the most widely used locoregional treatment for advanced hcc. but no solid evidences support the beneficial effect of the chemotherapy in tace. many advanced hcc patients also can't tolerate the locoregional chemotherapy. the p53 gene has multiple anticancer functions and does not have any of the immune-inhibitory effects of chemo- or radio-therapy. the objectives of this study are to investigate the efficacy and safety usingtae plus recombinant adenoviral human p53 gene (rad-p53) in treatment of advanced hcc.

study design: multicenter, open-labeled, active-controlled phase ii study study treatments: tace combined with rad-p53 injection vs.tace. the treatments are given once per 21 days until the disease progression. for the experiment group, 2 x 1000,000,000,000 viral particles of rad-p53 will be injected into the embolization artery. study objectives: efficacy and safety of the study treatments study endpoints: safety (adverse events, vital signs, lab tests, ecg and physical examination) and efficacy (progression-free survival, overall survival, and ecog ps)

Eligibility criteria:
inclusion criteria: 1. histopathologically diagnosed hcc; 2. unresectable; 3. over 18 years old; 4. with an eastern cooperative oncology group (ecog) score of 0-2; 5. with barcelona clinic liver cancer (bclc) stage of b or c; 6. with child-pugh score a or b; 7. with normal tests of hemogram, blood coagulation, liver and kidney function; 8. signed the informed consent form. exclusion criteria: 1. serious blood coagulation disorder, bleeding tendency, platelet \< 6 \* 1000000000/l; 2. have serious heart, lung function abnormalities or severe diabetes patients; 3. active infection; 4. liver function child-pugh grade c; 5. secondary and diffuse hepatocellular carcinoma patients; 6. extensive metastasis; 7. severe atherosclerosis; 8. aids patients; 9. serious thrombotic or embolic events within 6 months; 10. renal insufficiency requiring hemodialysis or peritoneal dialysis; 12. pregnant or lactating women; 13. mental disorder or disease.
predictive value of hbv pgrna on long-term outcomes in hepatitis b patients treated with antiviral therapy

Conditions: HBV; HCC

Summary: the goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of hbv pgrna in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis b. participants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.

this study is a prospective, exploratory, multi-center, real-world study, with huashan hospital as the leading unit. the study includes patients with chronic hepatitis b who have been determined by clinicians to start, or have already taken the first-line treatment { including pegylated interferon \[ifn\] monotherapy, a potent nucleos(t)ide analogue \[na\] monotherapy, two different potent nas combination therapy, or na plus ifn combination therapy. the study only collects clinical data and serum samples, without imposing any additional intervention measures or affecting any relevant clinical decisions. the clinical data is collected from the patient's clinical follow-up examination data, without additional visits and auxiliary examinations. sample collection during the necessary clinical examination and blood draw during the patient's treatment and follow-up, one additional serum separation tube (3ml) was drawn, without additional invasive examination for the patient. the study will follow up with patients for 5 years to explore the relationship between the serum hbv pgrna level and the endpoint event at different time points.

Eligibility criteria:
inclusion criteria: * chb defined as positive hepatitis b surface antigen at least 6 months, or hbv-related histological changes within 1 year if hbsag positive less than 6 months; * age between 18-80 years, gender is not limited； * patients with chronic hepatitis b who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon \[ifn\] monotherapy, a potent nucleos(t)ide analogue \[na\] monotherapy, two different potent nas combination therapy, or na plus ifn combination therapy; * patient who reads and signs informed consent. exclusion criteria: * patients with malignancies other than hepatocellular carcinoma.
dietary practices and locally advanced lung cancer (lungdiet)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: in recent years, fasting or the use of special diets (ketogenic, high protein, etc.), whether or not associated with food supplements, have increased substantially, particularly in oncology with the idea of improving for some of them, the tolerance of the proposed treatments, in particular emetogenic chemotherapy, or even to improve the prognosis. although there are preclinical data on cell cultures and in rats, the clinical data supporting these practices are very fragmented, with few trials carried out and only including small cohorts, mainly in the context of breast cancers. it is therefore very difficult to respond objectively to patients asking the question of the merits of these changes in dietary practices in the management of their cancer. the investigators want to carry out an inventory of the dietary practices of participating patients and their potential interest in fasting or special diets by means of a self-administered survey completed by the patient at diagnosis before treatment. this semi-quantitative self-administered survey (answers in never / sometimes / regularly / systematically) was developed by the nutrition and radiotherapy team of the georges-pompidou european hospital because there was no validated medical questionnaire on fasting or the use of special diets in oncology


Eligibility criteria:
inclusion criteria: * histologically documented inoperable stage iii non-small cell lung carcinoma (no metastasis) * treatment with curative intent including thoracic radiotherapy and at least one cycle of concomitant chemotherapy * patient informed and having signed the consent exclusion criteria: * sequential radiochemotherapy * metastatic forms from the outset * ear, nose, and throat (ent) or digestive pathologies interfering with normal oral nutrition * other concurrent or pre-existing cancer for less than 5 years at the diagnosis of bronchial cancer * patient under guardianship or curatorship * patient with cognitive impairment * patient not affiliated with a social security * patient under state medical help from french government * radiotherapy performed outside the ap-hp for cohort a and outside the hegp for cohort b

Keywords: radiochemotherapy fasting special diet
conceptualisation of a network approach to complete the classification of eating disorders with the aim of better personalising their management

Conditions: Eating Disorders; Eating Disorder Binge

Summary: eating disorders (edbs) are mental disorders with a great impact on the lives of individuals as well as a great cost imposed on society. the treatments currently available rely on different forms of psychotherapies with an unsatisfactory response rate as well as a considerable relapse rate . one of the reasons underlying the low success of available therapeutic modalities would be the heterogeneity of the clinical presentation of eds, making their classification and the personalization of their treatment more difficult.the investigators hypothesize that a secondarily dimensional classification approach (respecting the categorical classification currently in use) of eds based on the different dimensions disturbed in these disorders as well as in their comorbidities, would better represent their nosographic reality, which could provide patients with more personalized and potentially more effective care.

detailed description: the investigators will recruit a total of 840 patients with an eating disorder in the university hospital of montpellier. - participation consists of a one-day visit with a multidisciplinary assessment. no action is specific to research except the biological collection for the constitution of a genetic bank. this is the usual management of patients with eating disorders addressed to our department.

Eligibility criteria:
inclusion criteria: * patient with an eating disorder according to dsm-v criteria * patient aged from 15 to 65 years * patient who performs the day-hospital evaluation * patient affiliated to a french social security system * patient able to understand the nature, the aim and the methodology of the study * for minor one of the legal guardians gave his consent exclusion criteria: * patient in an unstable somatic state (eg severe metabolic disorder making impossible or unreliable neuropsychological assessments) * patient's refusal to participate * patient protected by law (guardianship or curatorship)\* * pregnant or nursing women. a dosage of βhcg will be performed to ensure the absence of pregnancy

Keywords: anorexia nervosa bulimia binge eating disorders neuropsychology neurocognitiond daily functioning
a study of monthly subcutaneous mircera for the treatment of chronic renal anemia in predialysis patients not treated with esa.

Conditions: Anemia

Summary: this single arm study will assess the efficacy and safety of subcutaneous methoxy polyethylene glycol-epoetin beta (mircera) for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with erythropoietin stimulating agents (esa). eligible patients will receive monthly subcutaneous injections of mircera at an initial recommended dose of 1.2 micrograms/kg. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * chronic renal anemia; * predialysis stage; * no esa therapy during previous 3 months. exclusion criteria: * transfusion of red blood cells during previous 2 months; * poorly controlled hypertension requiring hospitalization in previous 6 months; * significant acute or chronic bleeding.
evaluating the therapeutic effect of acupuncture on acute ischemic stroke patients

Conditions: Acute Stroke

Summary: the investigators design a randomized, single blinded, control study to evaluate the therapeutic effect of acupuncture in acute ischemic stroke patients:

acupuncture therapy in traditional chinese medicine has been verified in many disease by thousands years. due to the feasible and relatively safe in acupuncture management, now the west countries had been well document about acupuncture in medicine. the acupuncture therapy applied in post stroke functional recovery has been considered as more benefit than physical therapy only to post stroke rehabilitation. however, the effect of combined acupuncture therapy with standard management in acute stroke patient still remains unknown. the aim of this study is to evaluate the therapeutic effect of acupuncture in acute ischemic stroke patients. the prospective study was designed as a randomized, single blinded, control trial. we collected newly onset of acute ischemic stroke patient without underling systemic major illness, and randomized assign the collected patients into two groups as experimental (acupuncture)group and normal control group. the two groups both treat with routine western medicine as standard stroke therapy. the outcome measurement will evaluate by the changes from baseline at one and three months. the assessed scales including nih stroke scale, the barthel index, the functional independence measure score, the fugl-meyer assessment, and the modified rankin scale. we compared the all variable measurements to see if any benefit from acupuncture group than the control group.

Eligibility criteria:
inclusion criteria: * newly onset of acute ischemic stroke,exclusion criteria: * without underling systemic major illness

Keywords: acupuncture therap acute stroke randomized controlled trials
effects of plasmalogen on obese subjects

Conditions: Obesity

Summary: this is a 12-week, randomized, double-blind, placebo-controlled study to evaluate the effects of scallop-derived plasmalogen on brain fatigue, body weight and changes in blood plasmalogen in obese subjects aged 20-75 years old.


Eligibility criteria:
inclusion criteria: * willingness to provide informed consent to participate in the study * bmi ≥ 25 ㎏/㎡ * hba1c ≺ 8% without antidiabetic medication in the previous 3 months * stable medication for 3 months prior to the enrollment, and expectedly throughout the course of study exclusion criteria: * scallop allergy * symptomatic obesity, i.e., endocrinal, hypothalamic or drug-induced obesity * hypertension under medication with 4 or more drugs * hepatic disorder with ast ≥ 5 times upper limit of the normal range * mental disorder including schizophrenia and neurosis * alcohol dependence * history of malignancy for which treatment completed in the past 5 years * inflammatory disease * use of plasmalogen supplement in the past 3 months * ineligible condition as determined by study physician
study of sib-imrt in combination with 5-fu and mitomycin-c among patients with locally advanced anal canal cancer: efficacy, safety and quality of life

Conditions: Locally Advanced Anal Canal Cancer

Summary: anal canal carcinoma (acc) represents 1.2% of digestive cancers. its incidence is increasing. as epidermoid acc (95% of acc) are particularly sensitive to radio and chemotherapy, concomitant radio-chemotherapy is the standard treatment of locally advanced acc, with proven efficacy on locoregional control, anal sphincter preservation, progression-free survival and complete response rate higher than 80%. nevertheless, conventional radiotherapy frequently induces significant non-haematological toxicities requiring treatment interruptions. thus, treatment usually includes a chemotherapy (5-fluorouracil and mitomycine-c) and 25 fractions of 1.8 gy followed by a planned 1-week (or more) interruption and a boost, for a total 54-60 gy radiation dose over 9 weeks. considering the numerous anatomic pelvic structures, acc has become a localisation of interest for intensity-modulated radiation therapy (imrt) associated with less toxicity. however, imrt induces grade≥3 cutaneous toxicities requiring irradiation breaks. dose escalade did not show its interest: 60 grays remains the standard. assuming the deleterious effect of increased overall treatment time on local control and survival in head-and-neck and cervical cancers and the epidermoid histology of acc, the benefit of no irradiation break on acc tumour control is of interest. imrt offers the possibility to deliver different doses to different target volumes simultaneously by altered fractionation schedule like sib-imrt (simultaneously integrated boost-imrt). several sib-imrt schedules have been retrospectively evaluated. similar results were observed with moderate doses and schedules delivering higher doses with short interruptions. nevertheless, standard sib-imrt schedule in acc still not exist.


Eligibility criteria:
inclusion criteria: * who performance status ≤ 2 * age \> 18 years * epidermoid anal canal carcinoma histologically proven, locally advanced with an indication of radiation of pelvic and inguinal nodes concomitantly to chemotherapy * the t corresponds to the larger dimension of tumor at the rectal examination and the n is assessed by imaging pelvic mri-imaging, ct-scan, optionally pet-ct). eligible tumors are: t2 more than 4 cm n0-n3, t2-t4 n1-n3 or usn1, t3-t4 n0, m0 according to the 6th edition of the american joint committee on cancer staging manual. * laboratory data obtained ≤ 14 days prior to registration on study, with adequate bone marrow, hepatic and renal function defined as follows: hemoglobinemia, neutrophil, platelet counts, bilirubin and creatinin level * informed consent form exclusion criteria: * previous invasive cancer within 5 years except basocellular cancer and in situ cervical cancer * tumors with predominant skin involvement * presence of metastases * history of pelvic irradiation * contraindication to radiotherapy or chemotherapy * known hiv positive patients
change of range of motion of tmj after correction of pelvic a symmetry in women with cyclic pelvic pain

Conditions: Pelvic Pain

Summary: clinical experiences have shown that significant pain regression during a menstrual cycle has been often achieved by the use of spinal manipulative therapy (smt) indicated in women with primary dysmenorrhea with coexisting functional disorders of lumbosacral (ls) spine. namely, by activation of the nociceptive and vegetative system, ls spine disorders, before all segmental dysfunction and degenerative changes, can induce referred pain and reflex disturbances of pelvic organs (somatovisceral reflexes). since significant improvement or disappearance of pain during a menstrual cycle is often achieved with adequate therapy of coexisting vertebral disorders in women with primary dysmenorrhea, it is important to recognise latent or manifest vertebral disorders in dysmenorrheic women using clinical examination (grgić, 2009).


Eligibility criteria:
inclusion criteria: * the age of the participants will be ranged from 25 to 35 years. * their body mass index will be ranged from 20 to 25 kg/m2. * they will have regular menstrual cycle. * they will not receive any hormonal therapy or taking any regular drugs. exclusion criteria: the potential participants will be excluded if they meet one of the following criteria: * pelvic inflammatory diseases. * any pelvic pathological condition
live stream of prehospital emergency ultrasound in patients with acute dyspnoea

Conditions: Echocardiography; Acute Dyspnea

Summary: background: acute dyspnoea is a common symptom in prehospital emergency medicine. as ultrasound gained in importance for diagnosis in patients with acute respiratory distress, it plays even a role in the prehospital setting. however, prehospital emergency ultrasound (peu) remains challenging and requires knowledge and skills. new prehospital ultrasound devices offer the possibility for tele-supervision. the impact of tele-supervision of peu in patients with acute dyspnoea is unclear. objective: this prospective observational study aims to evaluate the effect of peu with tele-supervision on diagnosis, treatment strategies and cognitive load in comparison to peu without tele-supervision in patients with acute dyspnoea. methods: in total 350 prehospital emergency patients with acute dyspnoea will be included in this study. patients will be observed in two groups. in group 1 peu will be performed with tele-supervision, whereas in group 2 peu will be performed without tele-supervision (tele-supervision not available).


Eligibility criteria:
inclusion criteria: patients will be included, if they suffer from acute dyspnoea and at least one of the two following signs of respiratory failure: * respiratory rate \>20 breaths per minute * peripheral oxygen saturation without oxygen supplementation \<90% exclusion criteria: * under the age of 18 * if peu will lead to a delay of live-saving treatment or transportation * if patient rejects the peu, the patient will be excluded

Keywords: ultrasound diagnostics prehospital emergency medicine
famotidine versus placebo in emergency pediatric surgery as a risk to postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: the aim of this study is to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine versus placebo as a risk factor of ponv.

gastric ultrasound examinations will be performed preoperatively and postoperatively on patients undergoing emergency surgery in pediatric. gastric cross-sectional area (csa) will be measured, in order to estimate the gastric volume. the data that will be obtained will be used to evaluate a difference of the gastric volume between the two groups preoperatively and postoperatively and the possible relationship between the gastric volume difference and postoperative adverse event (ponv).

Eligibility criteria:
inclusion criteria: * pediatrics patients aging between 2-13 years . * pediatrics undergo urgent surgery (i.e., surgery that cannot be postponed for more than 48 h since clinical onset). * patientpediatrics come in trauma exclusion criteria: * patientpediatrics severly shocked . * patientpediatrics with diffusely distended abdomen as this will obstacle gastric ultrasound . * patientpediatrics with history of hypersenstivity to famotidine . * patientpediatrics with hepatic or renal impairments

Keywords: nausea,vomiting